Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780663 · ClinicalTrials.gov registry record · Phase 2
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
A Phase 2 study of Neuroendocrine Tumors and Carcinoid Tumor, sponsored by Cylene Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 13
- Study locations
NCT00780663 is a Phase 2 study of Neuroendocrine Tumors and Carcinoid Tumor that has completed, run by Cylene Pharmaceuticals. The registered enrollment target is 25 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (86% lower). The trial reports 13 study locations across 6 states.
The verdict
NCT00780663, a Phase 2 study of Neuroendocrine Tumors and Carcinoid Tumor, has completed, sponsored by Cylene Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is to evaluate the rate of clinical benefit response to quarfloxin treatment including the reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable hormones or other biochemical tumor markers.
Conditions Studied
Interventions
- DRUG Quarfloxin
Study Locations (13)
Texas
- Texas Oncology - Amarillo
- Texas Oncology - Dallas
- El Paso Cancer Treatment Center - El Paso
- Cancer Care Centers of South Texas - Kerrville
- UT Health Science Center - San Antonio
- Tyler Cancer Center - Tyler
Colorado
- Rocky Mountain Cancer Centers - Denver
- Front Range Cancer Specialists - Fort Collins
Washington
- Virginia Mason Medical Center - Seattle
- Northwest Cancer Specialists - Vancouver
Alabama
- Birmingham Hematology and Oncology - Birmingham
Florida
- - Ocala
New Mexico
- Southern New Mexico Cancer Center - Las Cruces
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780663
The ClinicalTrials.gov registry entry for NCT00780663 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (86% lower). The listed sponsor is Cylene Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which Quarfloxin is the first listed.
NCT00780663 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Texas, Colorado, Washington.
Frequently Asked Questions
What is clinical trial NCT00780663 about?
NCT00780663 is a clinical study titled "Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma". This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is to evaluate the rate of clinical benefit response to quarfloxin treatment including the reduction in secretory symptoms o...
What is the current status of trial NCT00780663?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-10. Estimated completion is 2010-03.
What conditions does trial NCT00780663 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Carcinoid Tumor.
What interventions are being tested in trial NCT00780663?
The interventions under investigation include: Quarfloxin (DRUG).
Who is sponsoring clinical trial NCT00780663?
This trial is sponsored by Cylene Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00780663 being conducted?
This trial has 13 study locations across Alabama, Colorado, Florida, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.